The abstract is read at the publisher; the summary is JClub's.
In acellular-pertussis–primed children aged 6–17 years, intranasal BPZE1 induced robust nasal S-IgA to Bordetella pertussis whole-cell extract, meeting the day-29 GMFR criterion (3·8 and 3·5).
- Why it matters: Current pertussis vaccines do not generate strong mucosal immunity, leaving a gap in protection at the site of infection. BPZE1’s mucosal IgA and adult protection motivate testing in children primed with acellular vaccines.
- What they did: In a phase 2b, randomized, observer-blinded trial across 16 sites (UK, Australia, Costa Rica), children received intranasal BPZE1 alone or with intramuscular Tdap, or Tdap with intranasal placebo. Primary outcome was day-29 nasal S-IgA GMFRs to whole-cell extract, with safety assessed for 7 days solicited events and 28 days unsolicited events.
- The result: BPZE1 was well tolerated, with predominantly mild-to-moderate solicited adverse events (48% with BPZE1, 67% with BPZE1+Tdap, 72% with Tdap). BPZE1 plus Tdap did not reduce Tdap serum IgG responses (GMRs 1·5, 1·1, 1·1) and all Tdap groups had ≥0·1 IU/mL anti-diphtheria and anti-tetanus toxoid antibodies at day 29.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.